Overview

To Compare Efficacy and Safety of CT-P16 and EU-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer

Status:
Active, not recruiting
Trial end date:
2023-08-01
Target enrollment:
0
Participant gender:
All
Summary
To demonstrate that CT-P16 is similar to US-approved Avastin in terms of efficacy determined by overall response rate (ORR) up to Cycle 6 during the Induction Study Period
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Celltrion
Treatments:
Bevacizumab
Criteria
Inclusion Criteria:

- diagnosed as recurrent disease or stage IV

- has at least 1 measurable lesion by Response Evaluation Criteria in Solid Tumor
(RECIST) Version 1.1

Exclusion Criteria:

- has predominantly squamous cell histology non-small cell lung cancer

- had surgery for metastatic nsNSCLC